Fair Prescription Drug Prices for Americans Act

The Fair Prescription Drug Prices for Americans Act would cap the U.S. list price for prescription drugs and biological products at the average price in Canada, France, Germany, Italy, Japan, and the United Kingdom. Drug manufacturers must annually report U.S. and international prices to the Health and Human Services Secretary, who calculates the six-country average. If a U.S. price exceeds this average, manufacturers face a civil penalty of 10 times the price difference per unit sold. The bill directly targets drug pricing practices without altering drug approval processes or insurance coverage.